Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses.

Abstract

Richter syndrome represents the evolution of chronic lymphocytic leukemia into an aggressive tumor, most commonly diffuse large B-cell lymphoma. The lack of <i>in vitro</i> and <i>in vivo</i> models has severely hampered drug testing in a disease that is poorly responsive to common chemoimmunotherapeutic combinations as well as to novel kinase inhibitors. Here we report for the first time the establishment and genomic characterization of two patient-derived tumor xenograft (PDX) models of Richter syndrome, RS9737 and RS1316. Richter syndrome xenografts were genetically, morphologically, and phenotypically stable and similar to the corresponding primary tumor. RS9737 was characterized by biallelic inactivation of <i>CDKN2A</i> and <i>TP53,</i> monoallelic deletion of 11q23 (<i>ATM</i>), and mutations of <i>BTK, KRAS, EGR2</i>, and <i>NOTCH1</i> RS1316 carried trisomy 12 and showed mutations in <i>BTK, KRAS, MED12</i>, and <i>NOTCH2</i> RNA sequencing confirmed that in both cases >80% of the transcriptome was shared between primary tumor and PDX. In line with the mutational profile, pathway analyses revealed overactivation of the B-cell receptor, NFκB, and NOTCH pathways in both tumors, potentially providing novel tumor targets. In conclusion, these two novel models of Richter syndrome represent useful tools to study biology and response to therapies of this highly aggressive and still incurable tumor.<b>Significance:</b> Two patient-derived xenograft models of Richter syndrome represent the first <i>ex vivo</i> model to study biology of the disease and to test novel therapeutic strategies. <i>Cancer Res; 78(13); 3413-20. ©2018 AACR</i>.